Advair Bioequivalence Guidance Falls Short of GSK’s Requests
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s draft guidance requires clinical study but sets a lower bar to generics of GSK’s blockbuster asthma and COPD treatment than company proposed; standards appear poised for warm reception from generic challengers.
You may also be interested in...
Generic Advair's Labeling Variation Stems From Permissible Design Differences, US FDA Says
Patient instructions for use of Mylan’s fluticasone/salmeterol generic are noticeably different from GSK’s reference listed drug but fall within the ‘different manufacturers’ exception to the ‘same labeling’ requirement.
Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs
The latest drug development news and highlights from our US FDA Performance Tracker.
CEO Shifts, Life Cycle Management On Agenda at Morgan Stanley
The Morgan Stanley Healthcare Conference attracted top management from big pharma, biotech and specialty firms, with Sanofi’s Elias Zerhouni commenting on the company’s strategy in Gaucher’s disease and Mylan expressing confidence in its ability to deliver on a generic Advair that meets FDA’s newly-issued proposed standards for substitutability.